Concord Drugs Limited (CONCORD) reported revenue of ₹20.94 Cr and net profit of ₹1.11 Cr for the quarter ended 2026-06-30. Figures are parsed from the company's filed results.
The statements below are read from Concord Drugs Limited’s filed results, 13 filed quarters and 5 fiscal years on record, consolidated basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: Q1 FY26-27 · filed Aug 10, 2026
| ₹ Cr | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026Latest | YoYlatest |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 8.98 | 7.53 | 12.8 | 15.6 | 11.7 | 12.4 | 10.8 | 10.4 | 13.6 | 10.3 | 17.0 | 37.9 | 20.9 | +53.9% |
| 7.52 | 5.91 | 12.2 | 15.3 | 10.9 | 11.5 | 9.40 | 9.35 | 12.6 | 9.18 | 16.0 | 36.4 | 18.7 | +48.2% | |
| Operating profit | 1.46 | 1.62 | 0.63 | 0.35 | 0.83 | 0.87 | 1.40 | 1.04 | 1.02 | 1.10 | 0.92 | 1.49 | 2.28 | +124.1% |
| OPM % | 16.3% | 21.5% | 5.0% | 2.2% | 7.1% | 7.0% | 12.9% | 10.0% | 7.5% | 10.7% | 5.4% | 3.9% | 10.9% | +3.4 pp |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.01 | — |
| Interest | 0.44 | 0.43 | 0.50 | 0.50 | 0.45 | 0.47 | 0.50 | 0.61 | 0.49 | 0.49 | 0.34 | 0.40 | 0.40 | -19.2% |
| Depreciation | 0.38 | 0.39 | 0.39 | 0.39 | 0.34 | 0.34 | 0.37 | 0.38 | 0.37 | 0.34 | 0.31 | 0.35 | 0.35 | -5.6% |
| Profit before tax | 0.64 | 0.80 | -0.26 | -0.54 | 0.04 | 0.07 | 0.53 | 0.06 | 0.16 | 0.27 | 0.30 | 0.75 | 1.54 | n/m |
| Tax % | 23.4% | 30.0% | n/a (loss) | n/a (loss) | 33.3% | 33.9% | 57.0% | 32.8% | 25.7% | 29.1% | 26.7% | 29.4% | 27.9% | +2.2 pp |
| Net profit | 0.49 | 0.56 | -0.24 | -0.34 | 0.03 | 0.04 | 0.23 | 0.04 | 0.12 | 0.19 | 0.22 | 0.53 | 1.11 | n/m |
| EPS (₹) | 0.53 | 0.60 | — | -0.34 | — | — | — | — | 0.12 | 0.31 | 0.16 | 0.47 | 0.85 | n/m |
